SJALL23T: Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL).

This document provides information on a newly launched clinical trial, NCT06390319, which aims to test the effectiveness of adding chemotherapy agents dasatinib or venetoclax to the treatment of children and young adults with T-cell acute lymphoblastic leukemia, lymphoma, or mixed phenotype acute leukemia. The trial will evaluate the rate of minimal residual disease (MRD)-negativity at the end of induction and assess event-free survival, overall survival, and toxicities. The trial is set to begin in May 2024 and is expected to be completed by December 2027. Additionally, the document mentions another clinical trial for the treatment of T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma, which involves the use of different drugs and interventions. This trial is not yet recruiting and aims to enroll 145 patients, with an estimated completion date of December 2033. The study is being conducted by St. Jude Children's Research Hospital in collaboration with AbbVie. [Extracted from the article]

Copyright of Hepatitis Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)